Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments


CancerNetwork spoke with Jason Luke, MD, FACP, at the SMR Conference regarding the latest updates on melanoma.

Jason Luke, MD, FACP of the UPMC Hillman Cancer Center spoke with CancerNetwork about the latest developments regarding melanocytes, dysregulated pathways and melanoma at the SMR Conference.


Well it’s become quite clear from a number of elegant studies from people like Boris Bastian and Hunter Shane about the progression of melanocytes picking up serial dysregulated oncogenes and overexpression of certain pathways. One of the surprising features about melanoma is that the BRAF that we target with BRAF-directed targeted therapies actually develops very early in melanocytes. Even moles have BRAF mutations and obviously moles are not melanoma. It’s now becoming clear that there’s a series of stages that these lesions go through, and that really points to our ability potentially to intervene at different places in the therapeutic context. So, we’re learning more and more about that. One of the talks at the SMR Meeting is going to be about single-cell—a dissection of the melanoma tumor—and I think as we learn about which of those cells specifically, at which stages are developing those dysregulated pathways, that might tell us where to place different treatments hopefully to avoid the development of metastatic melanoma over time.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content